Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01711905
Other study ID # 0315668
Secondary ID
Status Completed
Phase N/A
First received October 15, 2012
Last updated April 19, 2013
Start date November 2012
Est. completion date April 2013

Study information

Verified date April 2013
Source Martin-Luther-Universität Halle-Wittenberg
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Ministry of Education and Research
Study type Interventional

Clinical Trial Summary

The aim of this study is to investigate whether a supplementation of 20 µg Vitamin D3 per day for 12 weeks can be used to normalize vitamin d-Status


Description:

It is the objective of this study to investigate whether a supplementation with Vitamin D3 can be used to normalize insufficient vitamin d status and reduce atherosclerotic risk factors such as hypertension, inflammation and hyperlipidemia. The research question is whether Vitamin D3 reduces the level of systemic inflammation and whether Vitamin D3 has an effect on blood lipids.


Recruitment information / eligibility

Status Completed
Enrollment 107
Est. completion date April 2013
Est. primary completion date April 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- healthy volunteers

- age between 18 and 70 years

- informed consent

Exclusion Criteria:

- use of antihypertensive medication

- use of vitamin d or calcium supplements

- known renal, inflammatory or malignant diseases

- hypercalcemia or hypercalciuria

- participation in other clinical studies

- use of tanning booths during the study

- pregnancy or lactating period

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Vitamin D3
daily dosage of 20 µg Vitamin D3 for 12 weeks

Locations

Country Name City State
Germany Naturwissenschaftliche Fakultät III Halle/Saale Sachsen-Anhalt

Sponsors (2)

Lead Sponsor Collaborator
Martin-Luther-Universität Halle-Wittenberg German Federal Ministry of Education and Research

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary 25-hydroxyvitamin D3 major outcome variable is the increase of 25-hydroxyvitamin D3 in the treatment group in comparison with the placebo group after 12 weeks of supplementation Yes
Secondary atherosclerotic risk factors It is the objective of this study to investigate whether a supplementation with Vitamin D3 can be used to reduce atherosclerotic risk factors such as hypertension, inflammation and hyperlipidemia. The research question is whether Vitamin D3 can reduces the level of systemic inflammation and whether Vitamin D3 has an effect on blood lipids. after 12 weeks of supplementation Yes
Secondary inflammation It is the objective of this study to investigate whether a supplementation with Vitamin D3 can be used to reduce inflammation as an atherosclerotic risk factor after 12 weeks of supplementation Yes
Secondary hyperlipidemia It is the objective of this study to investigate whether a supplementation with Vitamin D3 can be used to reduce hyperlipidemia as an atherosclerotic risk factor after 12 weeks of supplementation Yes
See also
  Status Clinical Trial Phase
Completed NCT01554241 - Optimizing Vitamin D in the Elderly N/A
Completed NCT01422122 - Study of Vitamin D Supplementation on Improvement of Gums Health N/A
Terminated NCT02532062 - The Pittsburgh Vitamin D Study: Vitamin D Supplementation in Vitamin D-deficient Subjects at Risk of Lung Cancer N/A
Completed NCT01501916 - Effect of Vitamin D3 on Cardiovascular Risk Factors N/A
Completed NCT02921204 - Dietary Intake and Vitamin D Level in Adult Women N/A